Literature DB >> 8582893

Clinical perspectives of platelet transfusions: defining the optimal dose.

R G Strauss1.   

Abstract

To halt bleeding in patients with severe thrombocytopenia due to bone marrow failure, it is desirable to achieve a post-transfusion blood platelet count of 40 x 10(9)/L by platelet transfusions. Based on calculations of corrected count increments, each 1 x 10(11) platelets transfused will increase the blood platelet count approximately 10 x 10(9)/L per each square meter of patient body surface area. Thus, the post-transfusion blood platelet count will be approximately 20 x 10(9)/L following transfusion of 3 x 10(11) platelets to a 5 foot, 8 inch patient weighing 170 pounds (2.0 m2), who is bleeding because of a pre-transfusion platelet count of 5 x 10(9)/L. The post-transfusion platelet count likely will be even lower in sick patients (sepsis, amphotericin B plus antibiotic therapy, splenomegaly, graft-vs.-host disease, etc.) or if platelets are lost from the unit by leukofiltration before transfusion. Although a dose of 3 x 10(11) platelets is acceptable, in a regulatory sense for product quality, it is inadequate to control bleeding in most thrombocytopenic adult patients. Adjusting dose for body size, bleeding patients with pre-transfusion blood platelet of < 10 x 10(9)/L and weighing > 120 pounds should receive approximately 6 x 10(11) platelets, those weighing 30 to 120 pounds should receive 3 x 10(11) platelets, and infants weighing < 30 pounds (15 kg) should receive 5-10 ml/kg of platelet concentrate.

Entities:  

Mesh:

Year:  1995        PMID: 8582893     DOI: 10.1002/jca.2920100305

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Immature Platelet Count Levels as a Novel Quality Marker in Plateletpheresis.

Authors:  Ozlem Unay Demirel; Seyda Ignak; Mustafa Cagatay Buyukuysal
Journal:  Indian J Hematol Blood Transfus       Date:  2018-05-14       Impact factor: 0.900

Review 2.  Component therapy.

Authors:  K M Radhakrishnan; Srikumar Chakravarthi; S Pushkala; J Jayaraju
Journal:  Indian J Pediatr       Date:  2003-08       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.